BMEA
Price:
$10.5
Market Cap:
$380.21M
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.[Read more]
Industry
Biotechnology
IPO Date
2021-04-16
Stock Exchange
NASDAQ
Ticker
BMEA
According to Biomea Fusion, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.69. This represents a change of -14.80% compared to the average of -3.16 of the last 4 quarters.
The mean historical PE Ratio of Biomea Fusion, Inc. over the last ten years is -39.55. The current -2.69 PE Ratio has changed 580.11% with respect to the historical average. Over the past ten years (40 quarters), BMEA's PE Ratio was at its highest in in the June 2024 quarter at -1.07. The PE Ratio was at its lowest in in the June 2020 quarter at -155.32.
Average
-39.55
Median
-4.31
Minimum
-151.95
Maximum
-3.08
Discovering the peaks and valleys of Biomea Fusion, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 36.96%
Maximum Annual PE Ratio = -3.08
Minimum Annual Increase = -87.39%
Minimum Annual PE Ratio = -151.95
Year | PE Ratio | Change |
---|---|---|
2023 | -4.22 | 36.96% |
2022 | -3.08 | -28.49% |
2021 | -4.31 | -87.39% |
2020 | -34.19 | -77.50% |
The current PE Ratio of Biomea Fusion, Inc. (BMEA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.87
5-year avg
-39.55
10-year avg
-39.55
Biomea Fusion, Inc.’s PE Ratio is greater than Edgewise Therapeutics, Inc. (-24.40), less than Werewolf Therapeutics, Inc. (-1.59), greater than Cullinan Oncology, Inc. (-6.22), greater than Design Therapeutics, Inc. (-5.35), less than Ikena Oncology, Inc. (-1.27),
Company | PE Ratio | Market cap |
---|---|---|
-24.40 | $2.83B | |
-1.59 | $85.66M | |
-6.22 | $930.52M | |
-5.35 | $270.65M | |
-1.27 | $84.45M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Biomea Fusion, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Biomea Fusion, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Biomea Fusion, Inc.'s PE Ratio?
How is the PE Ratio calculated for Biomea Fusion, Inc. (BMEA)?
What is the highest PE Ratio for Biomea Fusion, Inc. (BMEA)?
What is the 3-year average PE Ratio for Biomea Fusion, Inc. (BMEA)?
What is the 5-year average PE Ratio for Biomea Fusion, Inc. (BMEA)?
How does the current PE Ratio for Biomea Fusion, Inc. (BMEA) compare to its historical average?